Evidence map›Paper›PMID 36322607›Full record

Observational studyPediatric blood & cancer2023

Multimodal phenotyping and correlates of pain following hematopoietic cell transplant in children with sickle cell disease.

Nitya Bakshi, Rachel Astles, Eric Chou, Asha Hurreh, Soumitri Sil, Cynthia B Sinha, Kolanda Ackey Sanders, Manasa Peddineni, Scott E Gillespie, Rohali Keesari and 1 more

Open access · hybridAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Pediatric blood & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Precision, integrative medicine for pain management in sickle cell disease.Frontiers in pain research (Lausanne, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Nitya BakshiDivision of Pediatric Hematology-Oncology-BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0002-0876-9506
Rachel AstlesEmory University School of Medicine, Atlanta, Georgia, USA.
Eric ChouRollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Asha HurrehJames T. Laney School of Graduate Studies, Emory University, Atlanta, Georgia, USA.
Soumitri SilDivision of Pediatric Hematology-Oncology-BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0001-7207-0524
Cynthia B SinhaDivision of Pediatric Hematology-Oncology-BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
Kolanda Ackey SandersAflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
Manasa PeddineniNova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, Florida, USA.
Scott E GillespiePediatric Biostatistics Core, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
Rohali KeesariPediatric Biostatistics Core, Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
Lakshmanan KrishnamurtiDivision of Pediatric Hematology-Oncology-BMT, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0003-3242-0037
Emory University · USAflac (United States) · USNova Southeastern University · US

Funding

Phase 2 RCT of Arginine Therapy for Pediatric SCD Pain IND #66,943 1/18/13 ActiveR01FD004814 · FDA · EMORY UNIVERSITY · PI MORRIS, CLAUDIA R · 2015 to 2018
$1.6M
Patient-Oriented Research in Arginine Deficiency SyndromesK24AT009893 · NCCIH · EMORY UNIVERSITY · PI Claudia R Morris · 2018 to 2026
$1.5M
STUDYING INTRA-INDIVIDUAL PAIN VARIABILITY IN SICKLE CELL DISEASE AND RESOLUTION OF PAIN AFTER HEMATOPOIETIC CELL TRANSPLANT: A NOVEL MODEL SYSTEM TO ELUCIDATE MECHANISMS OF TRANSITION TO CHRONIC PAINK23HL140142 · NHLBI · YALE UNIVERSITY · PI BAKSHI, NITYA · 2018 to 2022
$899k
Evidence-based Approaches to Chronic Pain Management in Youth with Sickle Cell DiseaseK23HL133457 · NHLBI · EMORY UNIVERSITY · PI SIL, SOUMITRI · 2017 to 2021
$748k
FDA HHS R01 FD004814NCCIH NIH HHS K24 AT009893NHLBI NIH HHS K23 HL133457NHLBI NIH HHS K23 HL140142
6 · The paper itself

Abstract

introductionThere is limited understanding of pain, patient-reported outcomes (PROs) of health-related quality of life (HRQoL), psychological factors, and experimental pain sensitivity before and following hematopoietic cell transplant (HCT) in children with sickle cell disease (SCD).

methodsIndividuals aged 8 years and older, English speaking, and scheduled for a HCT were invited to participate in an observational study where they completed assessments of pain, PROs, psychological factors, and qualitative interviews before and around 3 months, 6 months, 1 year, and 2 years post-HCT. An optional substudy of experimental pain sensitivity before and around 6 month, 1 year, and 2 years post-HCT was also offered.

resultsData from eight participants (median age 13.5 years, 25% female) with sickle cell anemia (SCA) or similarly severe genotype, and successful donor-derived erythropoiesis post-HCT are reported. We found that collection of pain, PROs, psychological factors, and qualitative data were feasible in the context of HCT. We found moderate to large differences in pain and some PROs between baseline to 1 year and baseline to 2 year post-HCT based on effect sizes, but only some differences were statistically significant. We found moderate to large differences in pressure pain threshold and moderate differences in cold pain threshold between baseline to 1 year and baseline to 2 year post-HCT based on effect sizes, but these differences were not statistically significant. Qualitative data indicated an improvement in pain and HRQoL post-HCT.

conclusionThis study provides a framework for the conduct of multimodal pain assessments before and after HCT, which is feasible but faced with unique barriers.

Indexed as

Anemia, Sickle CellHematopoietic Stem Cell TransplantationAdolescentChildFemaleHumansMalePainQuality of LifeTransplantation Conditioningpainpatient-reported outcomespediatric hematology/oncologyquality of lifesickle cell diseasetransplantation

Identifiers

PMID36322607
OpenAlexW4307930466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.